Send to

Choose Destination
Nat Rev Cancer. 2006 Aug;6(8):613-25.

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

Author information

Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA. MullerA@MLHS.ORG

Erratum in

  • Nat Rev Cancer. 2006 Sep;6(9):742.


Cancer immunotherapy has been predominantly focused on biologically based intervention strategies. However, recent advances in the understanding of tumour-host interactions at the molecular level have revealed targets that might be amenable to intervention with small-molecule inhibitors. In particular, key effectors of tumoral immune escape have been identified that contribute to a dominant toleragenic state that is suspected of limiting the successful implementation of treatment strategies that rely on boosting immune function. Within the context of the pathophysiology of cancer-associated immune tolerance, this Review delineates potential molecular targets for therapeutic intervention and the progress that has been made in developing small-molecule inhibitors.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center